Cases
One engine, every cohort.
Any product or program meant to change the body is a biomarker problem. Here is how the same engine applies across industries — from a chemo-recovery program to a crew bound for Mars. Each is an application of the engine, not a client roster.
By application
Programs and populations. Where a defined group's before/after panels become a measured outcome.
Recovery after chemotherapy
A patient cohort's panels before and after a recovery program — a measured profile shift showing what actually improved.
Read the case →
Analysis for private medical practices
A practice's incoming lab panels turned into structured, explainable reads — units, ranges and patterns, with an audit trail.
Read the case →
Workforce risk for self-insured employers
A workforce's panels read into risk tiers tied to claims cost — early detection where it moves the premium.
Read the case →
Crew health on deep-space missions
The hardest cohort in the universe — six physiological systems, 7+ months, no hospital. The extreme end of the same measurement.
Read the case →
By industry
Brands whose product changes the body. We turn a product's trial cohort into a measurable biomarker signature — the axis we read depends on what the product does.
Protein & functional bars
Cohort eats the bar for 12 weeks — we read the metabolic panel before and after (glucose, insulin, triglycerides, HOMA-IR).
Read the case →
Nutricosmetics & ingestibles
Beauty-from-within cohort over 8–12 weeks — systemic skin-aging markers (hs-CRP, oxidative stress, micronutrient status).
Read the case →
Cleaners & household chemicals
Households switch products for 6 weeks — exposure biomarkers (phthalate & paraben metabolites, inflammation).
Read the case →
Supplements & nutraceuticals
Cohort takes the supplement for 8–12 weeks — targeted nutrient plus downstream markers (omega-3 index, vitamin D, lipids, hs-CRP).
Read the case →
Patient stratification & trial enrichment
Screening-panel cohort before enrollment — the responder signature with N-of-M logic, so the trial arm reaches significance at a lower n.
Read the case →
See it on your cohort
Send one trial's before/after panels and we return a Signature Report: a measurable profile shift with an evidence trail.